1 guidelines therefore recommend adjusting dapt duration to individual patient needs Rates of er visits and hospitalizations for bleeding were higher with warfarin Mortality was higher with warfarin (3.7 versus 4.4 deaths/100 patient years, p=0.027) After propensity matching, 1,395 patients on rivaroxaban were compared to 4,185 patients on warfarin. Patients with advanced chronic kidney disease are considered to have disordered platelet aggregation leading to a higher bleeding risk. In this chapter, we will discuss the pathophysiology, epidemiology, and clinical features of thromboembolism and hemostasis, and their impact on cardiovascular outcomes
The study endpoints included ischemic (cardiovascular death, recurrent mi, and ischemic stroke) and major bleeding events. Dapt improves outcomes by lowering risk of ischemic events, including cardiac mortality and myocardial infarction (mi) Some of the improvement is attributable to a reduction in the incidence of stent thrombosis, a complication often associated with mi and death. Remarkable progress has been made in the pharmacological management of patients with cardiovascular disease, including the frequent use of antithrombotic agents. However, their safety profile, particularly concerning bleeding and thrombotic risks, remains a critical concern
WATCH
